Axa
JNCE

Axa’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Axa’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,100
Closed -$126K – 1260
2021
Q4 		$126K Sell
15,100
-20,700
-58% -$171K ﹤0.01% 1134
2021
Q3 		$266K Buy
35,800
+15,600
+77% +$96.6K ﹤0.01% 1154
2021
Q2 		$137K Sell
20,200
-47,600
-70% -$395K ﹤0.01% 1232
2021
Q1 		$696K Buy
67,800
+14,400
+27% +$158K ﹤0.01% 1037
2020
Q4 		$374K Hold
53,400
– – ﹤0.01% 1106
2020
Q3 		$436K Sell
53,400
-20,200
-27% -$125K ﹤0.01% 1059
2020
Q2 		$508K Hold
73,600
– – ﹤0.01% 1056
2020
Q1 		$350K Hold
73,600
– – ﹤0.01% 1026
2019
Q4 		$643K Buy
+73,600
New +$398K ﹤0.01% 956

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Axa's JNCE Position: Q1 2022 in Review

Axa sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 15,100 shares — an estimated $126K sold.

Axa first reported a position in JNCE in Q4 2019 and held it in 9 quarters. The position peaked at $696K in Q1 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Axa reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Axa sold 15,100 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $126K.
  • Axa first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
  • Axa's Jounce Therapeutics, Inc. Common Stock position peaked at $696K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Axa's 13F filing for Q1 2022, filed 13 May 2022.